Vacinas
Estudo randomizado | Imunogenicidade e reatogenicidade de diferentes vacinas de reforço após a primeira dose da vacina da J&J.
21 Jan, 2022 | 15:58h
Comentário no Twitter
Trial examined effects of boosting with one of the three approved #COVI19 vaccines — AD26.COV2.S, mRNA-1273, or BNT162b2 — 3 mos after the primary vaccination. All increased neutralizing-antibody levels & T-cell responses; mRNA vaccines were higher. https://t.co/qkpQFvNliJ pic.twitter.com/MUfa1OEsLP
— NEJM (@NEJM) January 19, 2022
Grupo de especialistas em emergências da OMS reafirma posição contra os “passaportes de vacina” para viagens internacionais.
21 Jan, 2022 | 15:53hEstudo de coorte retrospectiva de base populacional no Catar mostrou menor risco de infecção por Covid-19 após a vacina da Moderna em comparação com a da Pfizer–BioNTech.
20 Jan, 2022 | 23:17hEffectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar – New England Journal of Medicine
Comentário no Twitter
In two matched retrospective cohort studies comparing BNT162b2 and mRNA-1273, both were highly effective at preventing hospitalization & death. Breakthrough infections were lower among those who received mRNA-1273 than those who received BNT162b2. https://t.co/wgkrzfLNHz pic.twitter.com/E8hXIDFqWW
— NEJM (@NEJM) January 19, 2022
Pesquisadores descobrem que efeito placebo contribui para mais de 2/3 dos eventos adversos da vacina contra COVID-19.
20 Jan, 2022 | 22:19hComunicado de imprensa: Placebo effect accounts for more than two-thirds of COVID-19 vaccine adverse events, researchers find – Beth Israel Deaconess Medical Center
Estudo original: Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis – JAMA Network Open
Comentário: ‘Nocebo effect’: two-thirds of Covid jab reactions not caused by vaccine, study suggests – The Guardian
OMS afirma que não há evidência de que crianças e adolescentes saudáveis precisem de reforços da vacina contra Covid.
20 Jan, 2022 | 22:13hWHO says there’s no evidence healthy children and adolescents need Covid boosters – CNBC
[Ainda não publicado] Estudo feito em Israel mostra que reforço com 4ª dose de vacina contra COVID tem eficácia limitada.
20 Jan, 2022 | 21:37hVer também:
Israeli trial, world’s first, finds 4th dose ‘not good enough’ against Omicron – The Times of Israel
Israel study: 4th vaccine shows limited results with omicron – MedicalXpress
COVAX entrega bilionésima dose de vacina contra COVID-19 – mas 41% do mundo continua não vacinado.
20 Jan, 2022 | 21:36hVer também: COVID program delivers 1 billion doses to poorer countries – Associated Press
Conteúdos relacionados:
Is Covax finally going to vaccinate the world?
Perspective | A beautiful idea: how COVAX has fallen short.
WHO Launches Strategy to Achieve Global Covid-19 Vaccination by mid-2022.
WHO special envoys: To beat Covid, there’s a simple lesson – no one’s safe until everyone’s safe.
WHO COVAX Joint Statement: Call to action to equip COVAX to deliver 2 billion doses in 2021.
Covax: How will Covid vaccines be shared around the world?
Série de casos de síndrome da trombocitopenia com trombose após vacinação contra Covid-19 nos EUA.
20 Jan, 2022 | 21:18hLesões no ombro relacionadas à administração da vacina contra o SARS-CoV-2.
20 Jan, 2022 | 21:10hShoulder injury related to SARS-CoV-2 vaccine administration – Canadian Medical Association Journal
A iniciativa Covax vai finalmente vacinar o mundo?
20 Jan, 2022 | 20:10hIs Covax finally going to vaccinate the world? – Vox
Conteúdos relacionados:
Perspective | A beautiful idea: how COVAX has fallen short.
WHO Launches Strategy to Achieve Global Covid-19 Vaccination by mid-2022.
WHO special envoys: To beat Covid, there’s a simple lesson – no one’s safe until everyone’s safe.
WHO COVAX Joint Statement: Call to action to equip COVAX to deliver 2 billion doses in 2021.
Covax: How will Covid vaccines be shared around the world?